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Adoptive therapy with chimeric antigen receptor (CAR) redirected T cells recently showed remarkable anti-tumor efficacy
in early phase clinical trials; self-repression of the immune response by T-cell secreted cytokines, however, is still an issue
raising interest to abrogate the secretion of repressive cytokines while preserving the panel of CAR induced pro-
inflammatory cytokines. We here revealed that T-cell activation by a CD28-f signaling CAR induced IL-10 secretion, which
compromises T cell based immunity, along with the release of pro-inflammatory IFN-c and IL-2. T cells stimulated by a f
CAR without costimulation did not secrete IL-2 or IL-10; the latter, however, could be induced by supplementation with
IL-2. Abrogation of CD28-f CAR induced IL-2 release by CD28 mutation did not reduce IL-10 secretion indicating that
IL-10 can be induced by both a CD28 and an IL-2 mediated pathway. In contrast to the CD28-f CAR, a CAR with OX40
(CD134) costimulation did not induce IL-10. OX40 cosignaling by a 3rd generation CD28-f-OX40 CAR repressed CD28
induced IL-10 secretion but did not affect the secretion of pro-inflammatory cytokines, T-cell amplification or T-cell
mediated cytolysis. IL-2 induced IL-10 was also repressed by OX40 co-signaling. OX40 moreover repressed IL-10 secretion
by regulatory T cells which are strong IL-10 producers upon activation. Taken together OX40 cosignaling in CAR
redirected T cell activation effectively represses IL-10 secretion which contributes to counteract self-repression and
provides a rationale to explore OX40 co-signaling CARs in order to prolong a redirected T cell response.
Introduction
Adoptive cell therapy with chimeric antigen receptor (CAR)-
redirected T cells showed remarkable anti-tumor efficacy in
recent clinical trials.
1 Patients’ T cells are ex vivo engineered with
a CAR which redirects the T cell through the extracellular
antibody-derived binding domain toward target cells in a major
histocompatibility complex (MHC)-independent fashion.
2 CAR
intracellular signaling domain, which most frequently is the CD3f
endodomain derived from the T-cell receptor (TCR) complex,
mediates T-cell activation upon target engagement and initiates a
plethora of effector functions including the secretion of pro-
inflammatory cytokines, cytolysis of target cells and amplification
of redirected T cells. Both CD8
+ and CD4
+ T cells can specifically
be redirected by an engineered CAR; both T-cell subsets are
required for a potent and sustained anti-tumor response.
3 CAR
redirected T-cell activation, however, is short-term when no
appropriate costimulation simultaneously to CD3f signaling
occurs and when target cells lack costimulatory ligands. A
costimulatory endodomain like CD28 was therefore fused to
the CD3f CAR endodomain to prolong T-cell survival and to
produce efficient killing, cytokine release and T-cell prolifera-
tion.
4-7 Signaling through the fused CD28 endodomain thereby
strengthens the CAR redirected T-cell response through the
induction of IL-2 and the increase of IFNc.
4 Upon CD28 and
CD3f TCR mediated activation T cells upregulate “late”
costimulatory molecules of the tumor necrosis factor receptor
family including 4-1BB (CD137) and OX40 (CD134) which are
involved in prolonging T-cell persistence and inducing T-cell
memory.
8-10 For instance OX40 is upregulated 24 h after antigen
engagement in presence of CD28 costimulation
11,12 and further
augments CD28 activated T-cell responses with respect to pro-
liferation, cytokine responses and survival.
13,14 Several lines of
evidences imply that the success of a redirected T-cell therapy of
cancer depends on the maintenance of T cell effector functions
in the long-term which can be ensured by integrating the primary
TCR and CD28 signal with late costimulatory signals. Con-
sequently, Pule et al.
15 hypothesized that the combination of
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CD28 and OX40 endodomains in cis with CD3f in a CAR will
improve redirected T-cell effector functions and enhance anti-
tumor activity.
The T-cell response is physiologically limited by various
mechanisms, one of which are repressive cytokines like IL-10
which are present in high concentrations in the tumor micro-
environment, are produced by both tumor and stroma cells
and which impair an anti-tumor response.
16 CD28 costimula-
tion of T cells also induces IL-10 secretion
17 which in turn
compromises T-cell based immunity
18 through downregulation
of MHC molecules,
19 of the CD28 ligands CD80 and CD86
and of the intercellular adhesion molecule-1 (ICAM-1) on
antigen-presenting cells (APCs).
20,21 As a consequence the
antigen-driven T-cell amplification is turned off, the secretion
of pro-inflammatory cytokines is repressed and anti-inflammatory
cytokines are released which contribute to a further polarization
of the immune response. In addition to effector T cells, CD4
+
regulatory T (Treg) cells are potent IL-10 producers moreover
repressing the T-cell attack.
22 Adoptive T-cell therapy of cancer
aims to tip the balance by promoting T-cell activation while
reducing repression, both contributing to the overall therapeutic
success. We here revealed that (1) CD28-f CAR redirected T cells
upregulate IL-10 secretion upon antigen engagement, (2) IL-10
is also induced when f CAR T cells are activated in presence of
IL-2, and (3) that IL-10 induced by either mechanism can be
abrogated by co-signaling through OX40 in both CD4
+ helper
and regulatory T cells. Consequently, combined signaling through
a CD28-f-OX40 CAR repressed IL-10 without affecting the
other T-cell effector functions like secretion of pro-inflammatory
cytokines. We assume such dual costimulatory CAR of benefit
in improving T-cell anti-tumor immunity in long-term.
Results
We screened the cytokine profiles of CAR redirected human
CD4
+ T cells upon engagement of CAR-defined antigen. While
the CARs have the same extracellular binding domain for
carcinoembryonic antigen (CEA), the signaling moiety is com-
posed of the CD3f endodomain fused to the intracellular
CD28 or OX40 chain, respectively, providing different costimuli
(Fig.1A). Upon retroviral transduction, CARs were expressed
on the surface of human T cells with nearly same efficiencies
(Fig.1B). A CD3f CAR without costimulatory domain was
expressed in CD4
+ T cells for comparison. Engineered T cells
were co-incubated with CEA
+ and CEA
- tumor cells, respectively,
to record CAR-driven T-cell activation. Engineered T cells were
activated to secrete IFNc upon co-incubation with CEA
+ but
not with CEA
- tumor cells demonstrating the specificity of
CAR mediated T-cell activation (Fig.2A). IFNc secretion was
substantially enhanced by CD28 and OX40 costimulation,
respectively. IL-2, however, is secreted only upon CD28 co-
stimulation. T-cell amplification was most effectively induced
by the CD28f CAR and less by f and fOX40 CAR stimula-
tion (Fig.2B). CD28f CAR engagement moreover induced
secretion of IL-10 in high levels which were much lower with-
out CD28 or with OX40 costimulation.
Since CD28 costimulation in contrast to OX40 additionally
induced IL-2, we asked whether IL-10 secretion is induced by
IL-2 independently of costimulation. To address the question in
a thoroughly controlled setting, fCAR engineered T cells were
specifically stimulated by the immobilized anti-idiotypic anti-
body BW2064, which is directed toward the scFv CAR domain,
in presence or absence of added IL-2. As shown in Figure3,
Figure1. CAR expression by engineered T cells. (A) Schematic diagram of the expression cassettes for the anti-CEA chimeric antigen receptors (CARs)
which harbor the same extracellular binding domains and different signaling endodomains. TM: transmembrane domain. (B) CD4
+ T cells were
retrovirally transduced to express the respective CAR on the cell surface. CAR expression was recorded by incubation with a FITC-conjugated anti-CD3
mAb and a PE-conjugated anti-human IgG1 mAb, which binds to the extracellular CAR spacer domain, and analyzed by flow cytometry.
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IL-2 enhanced, along with IFNc, IL-10 secretion of f CAR
engineered T cells upon CAR engagement with antigen. IL-2
did not induce IL-10 secretion, however, when T cells were
stimulated by the OX40f CAR. As controls IL-2 increased
IL-10 secretion by CD28f CAR modified T cells whereas IL-2
did not induce IL-10 in non-modified T cells without f stimula-
tion. Taken together, IL-2 in the context of f CAR signaling
induced IL-10 which is not the case in presence of OX40
costimulation.
Since CD28f CAR signaling induced IL-2 secretion we asked
whether IL-10 secretion is due to autocrine acting IL-2 upon
CD28 mediated release. We abrogated IL-2 release by abrogating
lck binding to CD28 by mutation of the lck binding motif in
the CAR CD28 signaling moiety. CD4
+ T cells were engineered
with the mutated CD28Df CAR or for comparison with the f
and CD28f CAR, respectively, and stimulated through binding to
the CAR antigen. As summarized in Figure4, the CD28D CAR
did not induce IL-2 secretion while IL-10 and IFNc secretion are
not altered compared with the wild-type CD28f CAR. Cytokine
secretion was specifically induced by CAR engagement of antigen
because coincubation with an irrelevant antigen did not induce
IL-10 secretion. Data indicate that at least two pathways can
induce IL-10 secretion in CAR engineered T cells, one via IL-2
and the other via CD28 independently of IL-2 induction.
Figure2. CD28f CAR induces IL-10 secretion by engineered T cells. CD4
+ T cells were engineered with the anti-CEA CAR and (A) coincubated
(1.25  10
3−1  10
4 CAR T cells/well) for 48 h with CEA
+ LS174T or CEA
- Colo320 tumor cells (each 2.5 x 10
4 cells/well) or (B) incubated (2.5 x 10
4/well)
in microtiter plates that were coated with 10 mg/ml of the CAR-specific anti-idiotypic mAb BW2064 which binds to the CAR BW431/26 scFv domain
to specifically stimulate CAR T cells, or an isotype control mAb (IgG1). The number of CAR expressing T cells was adjusted to equal numbers by adding
non-transduced cells from the same donor. Cytokines in the supernatant were recorded by ELISA, proliferation was determined by BrdU incorporation.
Data represent the mean of triplicates ± standard error of the mean (SEM).
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Since fOX40 CAR redirected T cells did not produce IL-10
in presence of added IL-2, we asked whether OX40 costimula-
tion prevents CD28 mediated IL-10 secretion. To address the
issue, we made use of a CD28-OX40 dual costimulatory CAR.
For comparison, we used a CD28Df and CD28DOX40 CAR
which were deficient in IL-2 induction. CARs were expressed
in CD4
+ T cells and triggered by immobilized, CAR-specific
antigen. As summarized in Figure5, CD28f CAR T cells did
not secrete IL-10 when costimulated by OX40. IL-10 is also
repressed in presence of OX40 co-signaling when T cells were
stimulated by the mutated CD28Df CAR. For comparison, all
CARs induced similar amounts of secreted IFNc indicating a
similar T cell activation potency. IL-2 is secreted upon CD28f
and CD28fOX40 CAR signaling indicating the functional
integrity of the CD28 domain while IL-2 is not induced by the
mutant CD28Df and the CD28DOX40 CAR as expected. In
summary, data indicate that OX40 in a combined CD28-OX40
CAR repressed CD28 induced IL-10 secretion by redirected
T cells.
Treg cells are strong producers of IL-10. We therefore asked
whether CAR mediated OX40 co-signaling does also repress




were isolated from the peripheral blood (Fig.6A). Cells were
activated and expanded as recently described.
23 Expanded cells
were verified as Treg cells by a standard suppressor assay
(Fig.6B). We engineered Treg cells with CD28f and
Figure3. Added IL-2 induced IL-10 secretion in f CAR, but not in f-OX40
CAR stimulated T cells. CAR engineered CD4
+ T cells (2.5  10
4 cells/well)
were incubated for 48 h in the presence of added IL-2 (10–1,000 U/ml)
in microtiter plates coated with the CAR-specific anti-idiotypic mAb
BW2064 (2.5 mg/ml coating solution). Plates coated with an antibody
of irrelevant specificity served as control (w/o). Culture supernatants
were recorded for cytokines by ELISA. Data represent the mean
of triplicates ± SEM. A representative experiment out of three is shown.
Figure4. The modified CD28Df CAR which lacks IL-2 induction also
mediated IL-10 secretion. The anti-idiotypic mAb BW2064 which binds
to the scFv domain of the CAR and an isotype control mAb IgG1 were
coated onto microtiter plates (10 mg/ml coating solution). CD4
+ T cells
were engineered to express CARs with f, CD28f and CD28Df signaling
domains, respectively, and incubated for 48 h in coated microtiter plates
(2.5  10
4 CAR T cells/well). Culture supernatants were tested by ELISA
for IFNc, IL-2 and IL-10, respectively. The assays were performed
three times in triplicates; data represent mean values ± SEM of a
representative experiment.
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CD28OX40 CARs with similar efficiencies (Fig.6C). Upon
CD28f and CD28OX40 CAR redirected activation, Treg cells
secreted same amounts of IFNc indicating a similar degree in
CAR mediated activation (Fig.6D). No IL-2 is induced as
expected for Treg cells. CD28f CAR modified Treg cells,
however, secreted high amounts of IL-10 which were substanti-
ally reduced when redirected by the CD28OX40 CAR. Data
indicate that OX40 costimulation as provided by a CD28OX40
CAR repressed IL-10 secretion in Treg cells as it did in effector
T cells.
Discussion
We here demonstrate that CD28f CAR redirected T cells secrete
high amounts of IL-10 which is also the case when f CAR T cells
were stimulated in presence of IL-2. Since CD28Df CAR T cells
which do not produce IL-2 upon CAR engagement still secrete
IL-10 we conclude that IL-10 secretion by activated T cells can be
induced by CD28 costimulation independently of IL-2 signaling.
Simultaneous OX40 costimulation by a CAR repressed both IL-2
and CD28 mediated IL-10 secretion. IL-10 repression was not
Figure5. OX40 costimulation repressed CD28 CAR mediated IL-10 secretion in redirected T cells. Serial dilutions of the anti-idiotypic mAb BW2064 and
an isotype control mAb IgG1 were coated onto microtiter plates (0.01–10 mg/ml). CD4
+ T cells were engineered with the CEA-specific CD28f, CD28Df,
CD28OX40, and CD28DOX40 CAR, respectively, and incubated for 48 h in coated microtiter plates (2.5  10
4 CAR T cells/well). Culture supernatants were
recorded by ELISA for IFNc, IL-2 and IL-10, respectively. The assays were performed three times; data represent mean values of triplicates ± SEM of a
representative experiment.
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Figure6. For figure legend, see page 464.
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due to an impaired overall signaling because IFNc and IL-2
secretion were not altered by OX40 costimulation.
Endodomains from single costimulatory molecules linked to
CD3f in a CAR are sufficient to activate the killing machinery
and to increase T-cell proliferation and IFNc release.
24 OX40
and 4-1BB CARs less enhance T cell proliferation when inserted
in cis in a fCAR compared with a CD28f CAR.
24 OX40
cosignaling did not substantially increase the cytolytic activity
and T cell amplification. While CD3f CAR T cells fail to sustain
their function in the long-term, T cells redirected by the CD28-
OX40 CAR produced lasting anti-tumor activity in a xenograft
metastatic model.
6,25 CD28-OX40 redirected T cells, however,
were unable to completely eradicate the disease which may be
due in part to inefficiently sustaining human T cell function in
the mouse. We assume that the combined CD28-OX40 CAR
signaling moreover promotes the expansion of naïve T cells in
absence of the appropriate ligands on target cells or APCs. While
CD28 activation initiates clonal expansion of naïve T cells and
IL-2 secretion, in the absence of additional cooperative signals
only a small number of antigen-responding T cells persist and the
majority of T cells undergo apoptosis.
26 In this context fusion of
the “late” costimulatory OX40 signal in cis to the CD28f “early”
signal in a combined CAR will be of benefit compared with
OX40 or CD28 costimulation only. Consequently, incorporation
of the OX40 signaling domain favors the expansion, persistence
and effector functions of those cells
27 which likely occurs because
both costimulatory domains produce greater activation of NFkB
than either domain alone. CD28 and OX40 activate NFkB
by different pathways, i.e., CD28 via Vav and PI3K and OX40
via TRAF2. NFkB independent signals via Akt and AP1 are
additionally transmitted.
10,28
The different costimulatory CARs produce different patterns
of secreted cytokines; CD28f CAR T cells in particular pro-
duce IL-2 and IL-10 which both were not secreted by fOX40
CAR T cells.
25 T cells redirected by the CD28-OX40 CAR
produced IL-2 and increased IFNc after stimulation which is in
accordance to previous reports.
6,15 The CD28Df CAR which did
not produce IL-2 due to the mutated lck binding domain in the
CD28 signaling moiety displays a more favorite panel of secreted
cytokines with high IFNc levels without providing IL-2
supporting Treg cell survival and repression.
29 Proliferation of
engineered effector T cells is likewise sustained by the modified
CAR. Pule et al.
15 reported that CD3f and OX40f CAR T cells
did not produce IL-10, which is in accordance to our observation,
CD28-OX40 CAR T cells, however, were found to secrete IL-10
in nearly the same but hardly detectable levels as CD28 CAR
T cells. The divergent observation may be due to the different
arrangement of the signaling domains in cis described in the
Pule report,
15 i.e., a CAR with CD28 followed by OX40 followed
by CD3f, whereas we used a CAR with OX40 in a terminal
position. Both CARs have CD28 in a membrane proximal
position and have the same trans-membrane domain which
determines the level of surface CAR expression.
30 CARs in which
CD28 is merely membrane distal are not functional in CD3f
costimulation.
31 CARs with CD28 trans-membrane domain
show higher expression on the T-cell surface than CARs with a
CD3f membrane domain which is in accordance to Pule et al.
15
Combining “early” with “late” costimulatory signals in cis in a
CAR, however, has its limitation since it does not completely
recapitulate the temporo-spatial features of the sequential
signaling events as they physiologically occur to sustain T-cell
activation.
7,27
Repression of IL-10 by signaling through a CD28-f-OX40
CAR likely prevents auto-repression of CAR redirected T cells
through a prolonged cellular immune response. IL-10 repression
will moreover be of interest when combining the “T-body”
approach with vaccination against tumor associated antigens
32
and prevent accumulation of IL-10 in the tumor microenviron-
ment that in turn may compromise the anti-tumor response.
16
There may be concerns to transduce T cells by a retrovirus with
a CAR with strong and lasting proliferative signals. Retroviral
integration potentially can induce T cell acute lymphoblastic
leukemia due to LMO2 overexpression in patients with X-linked
severe combined immunodeficiency who received hematopoietic
stem cells engineered to constitutively express the common
c-chain receptor.
33 In contrast to retroviral modification of
hematopoietic stem cells, engineering mature T cells in




Cell lines and reagents. 293T cells are human embryonic
kidney cells that express the SV40 large T antigen.
36 The CEA-
expressing colon carcinoma cell line LS174T (ATCC CCL 188)
and the CEA-negative cell line Colo320 (ATCC CCL 220.1)
were obtained from ATCC. The anti-CEA mAb BW431/26 and
the anti-id mAb BW2064/36 with specificity for the anti-CEA










- T cells were isolated from peripheral blood by MACS procedures. Isolated T cells were incubated with anti-IL-7R-
FITC, anti-CD25-PE and anti-CD4-APC mAbs, respectively, and analyzed by flow cytometry. (B) Isolated T reg cells were activated and expanded in
the presence of IL-2 (1,000 U/ml) on solid phase bound agonistic anti-CD3 and anti-CD28 mAbs (each 10 mg/ml). Cells were rested for 48 h without
stimuli and tested for suppressor activity. Allogeneic CD4
+ responder cells (1  10
4 cells/well) and Treg cells (1  10
4 cells/well) were cocultivated for 5 d




- regulatory T cells express CARs with high efficacy. Isolated CD4
+CD25
+IL-7R
- regulatory T cells were retrovirally transduced
to express the anti-CEA CARs which harbor either the CD28f or CD28OX40 signaling domain. CAR engineered T cells were detected by a PE-conjugated




- T cells were engineered with the CD28f or CD28-CD3fOX40 CAR, respectively, adjusted to equal numbers of CAR expressing
cells and incubated for 48 h in coated microtiter plates (1  10
4 CAR T cells/well). Culture supernatants were recorded by ELISA for IFNc, IL-2 and IL-10,
respectively. The assays were performed three times; data represent mean values of triplicates ± SEM of a representative experiment.
464 OncoImmunology Volume 1 Issue 4© 2012 Landes Bioscience.
Do not distribute.
mAb BW431/26 were described earlier.
37 OKT3 (ATCC CRL
8001) is a hybridoma cell line that produces the anti-CD3 mAb
OKT3. All cell lines were cultured in RPMI 1640 medium, 10%
(v/v) FCS (all Life Technologies). OKT3 mAb was affinity
purified from hybridoma supernatants utilizing goat anti-mouse
IgG2a antibodies (Southern Biotechnology) that were immobi-
lized on N-hydroxy-succinimid-ester-(NHS)-activated sepharose
as recommended by the manufacturer (Amersham Biosciences).
The goat anti-human IgG antibody and its biotin-, FITC- or PE-
conjugated F(ab´)2 derivatives were purchased from Southern
Biotechnology. The anti-IFNc mAb NIB42 and the biotinylated
anti-IFNc mAb 4S.B3, the anti-IL-2 mAb 5344.111 and the
biotinylated anti-IL-2 mAb B33–2, and the anti-human IL-10
mAb 4D5 and the biotinylated anti-human IL-10 mAb 6D4/D6/
G2 were all purchased from BD Bioscience.
Generation and expression of recombinant anti-CEA CARs.
The generation of the retroviral expression cassettes for the
recombinant BW431/26-scFv-Fcf, the BW431/26-scFv-Fc-
CD28f, the BW431/26-scFv-Fc-OX40 and the BW431/26-
scFv-Fc-CD28OX40 CARs was described in detail.
4,24,38
Retroviral transduction of T cells with CARs was described in
detail elsewhere;
36,38 CAR expression was monitored by flow




high regulatory T cells was per-
formed as recently described.
23 The CD28 endodomain with a
mutated Lck binding motive was generated by site-directed
mutagenesis. Briefly, retroviral expression vectors for recombinant
CARs harboring a chimeric CD28f or CD28OX40 signaling
domain were PCR-amplified utilizing the following oligonucleo-




The reaction product was treated with DpnI, transformed into
E. coli DH5, and mutations were verified by sequence analysis.
Magnetic activated cell sorting (MACS). Peripheral blood
lymphocytes from healthy donors were isolated by density
centrifugation and monocytes were depleted by plastic adherence.
Non-adherent lymphocytes were washed with cold PBS contain-
ing 0.5% (w/v) BSA, 1% (v/v) FCS, 2 mM EDTA. CD4
+ T cells
were isolated by magnetic activated cell sorting (MACS) utilizing
the “CD4
+ T cell isolation kit” (Miltenyi Biotec) routinely
resulting in . 95% purity. CD4
+CD25
+FoxP3
high Treg cells were
isolated utilizing the “Treg isolation kit II” (Miltenyi Biotec).
Immunofluorescence analyses. CAR engineered T cells were
identified by two color immunofluorescence utilizing a PE-
conjugated F(ab’)2 anti-human IgG1 antibody (0.1 mg/ml) and a
FITC-conjugated anti-CD3 mAb (UCHT-1, 1:20). Regulatory
T cells were identified by multi color immunofluorescence
utilizing an APC-conjugated anti-CD4 mAb (Dako), a PE-
conjugated anti-CD25 mAb (Miltenyi) and a FITC-conjugated
anti-CD127 (IL-7R) mAb (eBioscience). Immunofluorescence
was analyzed using a FACScan
TM cytofluorometer equipped with
the CellQuest research software (Becton Dickinson).
CAR mediated T cell activation. CD4
+ T cells were engineered
with anti-CEA CARs and cultivated in the presence or absence
of exogenous IL-2 (10–1,000 U/ml) in microtiter plates
(Polysorb, Nunc, Roskilde, Denmark) (2.5  10
4 receptor grafted
T cells/well) which were pre-coated with the anti-idiotypic mAb
BW2064 or an IgG1 mAb for control (each 0.01–10 mg/ml). In
another set of experiments CAR engineered T cells were
cocultivated for 48 h in 96-well round bottom plates with
CEA
+ LS174T and CEA
- Colo320 tumor cells (each 2.5  10
4
cells/well). After 48 h culture supernatants were analyzed by
ELISA for IFNc, IL-2 and IL-10 secretion, respectively. Briefly,
cytokines in the supernatants were bound to the solid phase
capture antibodies (each 1 mg/ml) and detected by the
biotinylated detection antibodies (each 0.5 mg/ml). The reaction
product was visualized by a peroxidase-streptavidin-conjugate
(1:10,000) and ABTS
1 (Roche Biochemicals, Mannheim,
Germany). T cell proliferation was determined by BrdU-
incorporation utilizing the “5-Bromo-2'-deoxy-uridine Labeling
and Detection Kit III” (Roche Biochemicals).
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